How should an axillary cyst be evaluated and treated?

Evaluation and Management of an Axillary Cyst

For any new palpable axillary cyst or mass, perform axillary ultrasound as the initial imaging study to distinguish solid from cystic lesions and evaluate lymph node morphology, followed by diagnostic mammography or digital breast tomosynthesis to exclude an occult breast primary. 1

Initial Diagnostic Approach

First-Line Imaging

• Axillary ultrasound is the cornerstone test because it definitively differentiates true cysts from solid masses and characterizes lymph node architecture (cortical thickness, hilum integrity, vascularity). 2, 1
• Combine ultrasound with diagnostic mammography or digital breast tomosynthesis on the same side to rule out occult breast malignancy, which accounts for approximately 7% of axillary masses in women without known cancer (prevalence increases with age). 1

Key Ultrasound Features to Document

• Benign-appearing cystic lesions show: anechoic or hypoechoic fluid content, smooth walls, posterior acoustic enhancement, and no internal vascularity. 3
• Epidermal inclusion cysts (a common benign cause) demonstrate: oval subcutaneous mass with dermal attachment, intralesional echogenic reflectors, filiform anechoic areas, and absent vascularity. 3
• Lymph nodes with preserved fatty hilum suggest benign reactive adenopathy and can be observed. 1

When to Biopsy vs. Observe

Proceed Directly to Ultrasound-Guided Core Biopsy If:

• Complete loss of the central fatty hilum (highest positive predictive value 90–93% for malignancy). 2, 1
• Rounded rather than oval node shape. 1
• Increased vascularity on Doppler imaging. 1
• Cortical thickness >0.3 cm or short-axis diameter >1 cm. 2
• Any patient with known or suspected malignancy (breast, melanoma, lymphoma, head/neck cancer) regardless of imaging appearance—do not delay for vaccine-related adenopathy resolution. 1

Safe to Observe Without Biopsy If:

• Imaging confirms a simple benign cyst (anechoic, thin-walled, no solid component). 1, 3
• Lymph node with intact fatty hilum in a low-risk patient (no cancer history, no suspicious features). 1
• Vaccine-related adenopathy in a low-risk patient (ipsilateral to COVID-19 mRNA vaccine given ≤3 months prior, no cancer history)—expectant management without routine follow-up imaging is appropriate. 1

Special Considerations

Bilateral Axillary Masses

• Differential includes systemic disease (lymphoma, leukemia, autoimmune disorders), bilateral breast cancer (rare), or infectious/inflammatory conditions. 1
• Perform bilateral axillary ultrasound plus diagnostic mammography. 1
• If mammography is negative but nodes remain suspicious, breast MRI detects occult breast cancer in >66% of such cases. 1

Vaccine-Related Adenopathy Pitfalls

• High-risk patients (known malignancy) should proceed directly to tissue biopsy regardless of vaccination timing—do not delay cancer staging. 1
• Schedule screening mammography before vaccination or ≥4–6 weeks after the final vaccine dose to reduce false positives. 1

Treatment Algorithm

For Confirmed Simple Cysts

• No intervention required if asymptomatic. 3
• Excision indicated if the cyst causes discomfort due to large size (>4 cm), is growing, or causes functional impairment. 3

For Suspicious or Indeterminate Lesions

• Ultrasound-guided core-needle biopsy with marker-clip placement is the standard—fine-needle aspiration has lower sensitivity (52%) compared to core biopsy combined with ultrasound (sensitivity improves from 61% to 79%). 2, 1
• Core biopsy distinguishes benign from malignant pathology and guides definitive management. 4, 5

For Malignant Nodes

• In newly diagnosed breast cancer with positive axillary nodes, sentinel lymph node biopsy (SLNB) has replaced axillary lymph node dissection (ALND) as the standard, with non-inferior 10-year overall survival and markedly lower morbidity. 1
• Targeted axillary dissection (removal of clipped node plus sentinel nodes) is preferred in node-positive patients receiving neoadjuvant chemotherapy, lowering false-negative rates to 8.4–8.7% when ≥3 nodes including the clipped node are removed. 1

Critical Pitfalls to Avoid

• Do not use FDG-PET/CT as the initial imaging modality for an isolated axillary mass—it provides no diagnostic benefit. 1
• Do not perform routine ALND in clinically node-negative or limited node-positive breast cancer—SLNB offers equivalent survival with reduced morbidity. 1
• Do not delay biopsy in patients with known malignancy to await resolution of possible vaccine-related adenopathy. 1
• Do not rely on negative axillary ultrasound alone to rule out nodal disease—it has relatively low negative predictive value and sensitivity (26–94% sensitivity, 53–98% specificity). 2